The included biopsies were discordant for TI-NK cell content and response to treatment with anti-HER2 antibodies, but matched by patient age, tumor area and TIL score (Fig. 1A, B and Supplementary Fig. 1A). This evidence concerns the gene ERBB2 and neoplasm.